URL | https://www.thomasnet.com/insights/thermo-fisher-s |
Source | Thomas Insights |
Date Published | 03/24/2021 |
Author Name | Mike Hockett |
Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
Company/Division name | Thermo Fisher Scientific |
Type of work | Manufacturing |
Reshoring category: | Reshoring |
Year reshoring announced: | 2021 |
Year reshoring implemented or to be implemented: | 2022 |
Domestically, the work will be done: | In-house |
Capital investment ($): | 600 |
If relevant, work nearshored to: | - |
Industry(ies): | Chemicals |
Product(s) reshored | bioprocessing, biopharma, single-use technologies |
What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Other, Covid-19 |